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Abstract
A new application for omega-3 fatty acids has recently emerged, 
concerning the treatment of several mental disorders. This indication 
is supported by data of neurobiological research, as highly unsatu-
rated fatty acids (HUFAs) are highly concentrated in neural phospho-
lipids and are important components of the neuronal cell membrane. 
They modulate the mechanisms of brain cell signaling, including the 
dopaminergic and serotonergic pathways. The aim of this review is to 
provide a complete and updated account of the empirical evidence of 
the efficacy and safety that are currently available for omega-3 fatty 
acids in the treatment of psychiatric disorders. The main evidence for 
the effectiveness of eicosapentaenoic acid (EPA) and docosahexaeno-
ic acid (DHA) has been obtained in mood disorders, in particular in 
the treatment of depressive symptoms in unipolar and bipolar depres-
sion. There is some evidence to support the use of omega-3 fatty acids 
in the treatment of conditions characterized by a high level of impul-
sivity and aggression and borderline personality disorders. In patients 
with attention deficit hyperactivity disorder, small-to-modest effects 
of omega-3 HUFAs have been found. The most promising results have 
been reported by studies using high doses of EPA or the association 
of omega-3 and omega-6 fatty acids. In schizophrenia, current data 
are not conclusive and do not allow us either to refuse or support 
the indication of omega-3 fatty acids. For the remaining psychiatric 
disturbances, including autism spectrum disorders, anxiety disorders, 
obsessive-compulsive disorder, eating disorders and substance use 
disorder, the data are too scarce to draw any conclusion. Concerning 
tolerability, several studies concluded that omega-3 can be considered 
safe and well tolerated at doses up to 5 g/day.
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Introduction
The role of omega-3 highly unsaturated fatty acids (HUFAs) in 
human mental health has been widely studied in the last two decades.
Omega-3 fatty acids eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA) are derived from alpha-linolenic acid (ALA) 
and are dietary essential fatty acids. They cannot be synthetized de 
novo by mammals and are provided by supplementation, such as fish 
oil. 
EPA and DHA act as competitive inhibitors of omega-6 fatty ac-
ids causing a reduction in the synthesis of pro-inflammatory media-
tors [1]. In fact, the omega-6 family of fatty acids is converted to ara-
chidonic acid and then into prostaglandins and leukotrienes, which 
are responsible of the pro-inflammatory effects. Therefore, a diet rich 
in fish oil has been shown to decrease the incidence of inflammatory 
diseases.
In addition, HUFAs slow coronary atherosclerosis by optimiz-
ing cholesterol concentrations and lowering plasma triglyceride lev-
els. HUFAs also have antithrombotic, antiarrhythmic and vasodila-
tory properties, providing the protection of the cardiovascular system 
and significantly diminishing cardiovascular mortality. These effects 
of omega-3 fatty acids have supported indications in the secondary 
prevention of hypertension, coronary heart disease, type 2 diabetes 
and in some cases of rheumatoid arthritis, Crohn’s disease, ulcerative 
colitis, chronic obstructive pulmonary disease and renal disease [2,3].
EPA and DHA are important for fetal development, including 
neuronal, retinal and immune functions [4].
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In recent years, the interest of omega-3 fatty acids has grown in 
psychiatry, and their role in the treatment of several mental diseases 
has been investigated. HUFAs are important components of phos-
pholipids and cholesterol esters of the neuronal cell membrane, es-
pecially of dendritic and synaptic membranes. The rationale for the 
use of these new agents in psychiatric disorders stemmed from their 
primary action in producing modification of the synaptic membrane 
[5]. Indeed, they modulate and are involved in brain cell signaling, in-
cluding monoamine regulation [6-10], modification of receptor prop-
erties or the activation of signal transduction by receptors.
Among psychiatric diseases, long-chain omega-3 fatty acids have 
been tested in the treatment of schizophrenia, unipolar and bipolar 
mood disorders, anxiety disorders, obsessive-compulsive disorder, 
attention deficit hyperactivity disorder (ADHD), autism, aggression, 
hostility and impulsivity, borderline personality disorder, substance 
abuse and anorexia nervosa. The aim of this review is to provide an 
updated account of the empirical evidence of the efficacy and safety 
that are currently available for omega-3 fatty acids in the treatment 
of mental disorders. In particular, we focused on the data of efficacy 
and the adverse effects of different doses of HUFAs in the treatment 
of mental disorders, to determine which dose levels of single or com-
bined fatty acids are related to a good clinical response of specific 
mental disorders with a low risk of significant adverse effects.
Methods
This review presents and critically evaluates data from clinical 
trials, systematic reviews and meta-analyses published from 1980 
to September 2015, after a systematic research on the Medline data-
base provided by the U.S. National Library of Medicine (http://www.
ncbi.nlm.nih.gov/pubmed?otool=iitutolib). The search terms were: 
omega-3 fatty acids; HUFAs; eicosapentaenoic acid; docosahexae-
noic acid; ethyl-eicosapentaenoic acid; α-lipoic acid; α-linoleic acid; 
psychiatric disorders; psychotic disorders; schizophrenia; mood dis-
orders; anxiety disorders; obsessive-compulsive disorder; attention 
deficit hyperactivity disorder; autism spectrum disorders; aggression, 
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hostility, impulsivity; personality disorders; borderline personality 
disorder; substance dependence; anorexia nervosa; adverse effects; 
dose.
Schizophrenia
Studies of post mortem samples have shown that patients with 
schizophrenia have often low levels of EPA and DHA in their brain 
cells. The level of fatty acids is considered important to maintain the 
correct nerve cell-membrane metabolism [11]. The evidence is strong 
enough to have led to a ‘membrane phospholipid hypothesis’ of schiz-
ophrenia [12,13]. Based on findings that in individuals with schizo-
phrenia or related psychotic disorders, certain omega-3 and omega-6 
HUFA levels are reduced compared to healthy control samples, the 
idea that restoration of HUFA resources could be used as a treatment 
option in psychotic disorders has been widely discussed [14].
To date, there are 13 RCTs available concerning the role of ome-
ga-3 fatty acids supplementation in schizophrenia or related disorders. 
For ethical and clinical reasons, most trials used the add-on strategy, 
including patients who already received neuroleptics or atypical an-
tipsychotics. Two exceptions are the studies published by Amminger 
[15] and Markulev [16], which considered patients at high risk for 
developing psychosis. Peet et al. [17] and Emsley et al. [18] designed 
trials with omega-3 HUFAs as a monotherapy, but in both cases, al-
most all patients needed to be treated also with an antipsychotic drug 
during the course of the trial. Only six RCTs [15,17,19-22] reported 
that HUFAs had a benefit on positive or negative symptoms. The sam-
ple size of all of the reviewed studies was small, and the population 
investigated suffered from a considerable degree of heterogeneity. In 
fact, not only patients with a diagnosis of schizophrenia were includ-
ed, but also subjects with schizoaffective disorder [23], first episode 
of psychosis [21,24] and resistant schizophrenia [19]. The omega-3 
supplementation has been administered in a dosage ranging from 1–4 
g/day. The duration of the trials has been limited to 8–16 weeks in the 
majority of the studies. The main issue is that no conclusions could 
be drawn regarding the medium- to long-term effects of HUFAs in 
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schizophrenia, according to the findings of the four meta-analysis 
available on this topic [25-28] (Table 1).
Table 1: Double-blind controlled trials of highly unsaturated fatty acids (HUFAs) as 
an add-on strategy in the treatment of schizophrenia. PANSS, Positive and Negative 
Syndrome Scale; E-EPA, ethyl-EPA.
EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA = ethyl-eicos-
apentaenoic acid; α-LA = α-lipoic acid; UHR = ultra-high-risk; FEP = first episode of 
psychosis; ↓ = decrease of; ↑ = increase of.
Peet and colleagues [17] performed a 12-week placebo-con-
trolled trial in 30 males and 15 females on stable antipsychotic medi-
cation who were still symptomatic. Only 35 patients completed the 
trial. The authors found that EPA was more effective at the reduction 
of symptoms as assessed with the Positive and Negative Syndrome 
Scale (PANSS) in comparison to DHA and placebo. In the same year, 
Peet and colleagues [17] conducted a second RCT to test EPA (dose: 2 
g/day) as a monotherapy for schizophrenia. Thirty patients who never 
Study Drug and Dose Sample Treatment 
Duration 
Results
Peet et al., 
2001 [17]
EPA or DHA 2 g/day 45 patients 12 weeks ↓ psychotic symptoms measured with 
PANSS in the group treated with EPA
Peet et al., 
2001 [17]





E-EPA 1–4 g/day 115 patients 12 weeks ↓ positive symptoms measured with 
PANSS, ↓ depressive symptoms 
Jamilian et al., 
2014 [20]
1 g/day 60 patients 8 weeks ↓ psychotic symptoms measured with 
PANSS
Fenton et al., 
2001 [23] 
ethyl-EPA 3 g/day 87 patients 16 weeks no significant differences in posi-
tive, negative symptoms, mood or 
cognition
Berger et al., 
2007 [24]




EPA 700 mg/day + 
DHA 480 mg/day 
76 individuals 
“UHR” 




EPA + DHA 2.2 g/day 71 patients 
with FEP
26 weeks ↓ psychotic symptoms measured with 
PANSS ↓ depressive symptoms ↑ 
level of functioning 
Bentsen et al., 
2013 [22]
ethyl-EPA 2 g/day 99 patients 16 weeks ↓ impairment of the course of psy-
chosis
Emsley et al., 
2014 [18]
EPA 2 g/day + DHA 
1 g/day + α-LA 300 
mg/day
33 patients 2 years relapse prevention of psychotic 
symptoms
Emsley et al., 
2002 [29]
ethyl-EPA 3 g/day 40 patients 12 weeks ↓ positive symptoms and negative 
symptoms measured with PANSS
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assumed an antipsychotic agent with a recent diagnosis of schizophre-
nia were recruited. For ethical reasons, antipsychotic medications 
were permitted, so at the end of the study, only two patients remained 
without an antipsychotic treatment. The results indicated that patients 
treated with EPA, but also antipsychotics, improved more than place-
bo-treated subjects in psychopathology measured with the PANSS. In 
2002, Peet and Horrobin [19] administered ethyl-EPA to patients with 
resistant schizophrenia for 12 weeks. One hundred and fifteen sub-
jects, who were already in treatment with clozapine, olanzapine, risp-
eridone, quetiapine or a neuroleptic, were randomly assigned to pla-
cebo or 1, 2 or 4 g/day of ethyl-EPA arm in addition to antipsychotic 
drugs. Authors reported a significant improvement of the PANSS total 
score and subscales scores in the 2 g/day EPA-treated group, but there 
was also a large effect of placebo in patients receiving only typical or 
new generation antipsychotics. In contrast, in patients on clozapine, 
there was little placebo response, but a significant effect of augmenta-
tion with ethyl-EPA on all rating scales, PANSS, PANSS subscales and 
the Montgomery-Asberg Depression Rating Scale (MADRS).
More recently, Jamilian and colleagues [20] compared 1 g/day of 
non-specified omega-3 with placebo in 60 patients with schizophre-
nia who already assumed a standard antipsychotic medication. Ome-
ga-3 outperformed placebo significantly, based on the PANSS score.
Less encouraging findings were presented by Fenton and col-
leagues [23] who designed a 16-week study to evaluate the efficacy 
of ethyl-EPA (3 g/day) vs. placebo in 87 patients with schizophre-
nia or schizoaffective disorder with residual symptoms in treatment 
with conventional antipsychotics. The results indicated no significant 
differences in positive or negative symptoms, mood and cognition. 
Similar results were reported by Berger and colleagues [24], who per-
formed an RCT including 69 patients with first-episode psychosis 
who were treated for 12 weeks with a flexible dose of antipsychotic 
medication (risperidone, olanzapine or quetiapine) plus ethyl-EPA 
(E-EPA) (2 g/day) or placebo. The authors suggested that E-EPA may 
accelerate treatment response and ameliorate the tolerability of antip-
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sychotics, but they remained skeptical about the specific efficacy of 
EPA in early psychosis. 
Early treatment of the prodromal period of psychotic disorders 
has been linked to more favorable outcomes. The term ‘ultra-high-
risk’ (UHR) identifies individuals who are at increased risk of devel-
oping full blown psychotic symptoms. Treatment with omega-3 HU-
FAs may be an interesting treatment option for UHR subjects due to 
the low incidence of adverse effects. 
Amminger and colleagues [15] performed an RCT on 76 indi-
viduals with high risk for developing psychosis comparing omega-3 
HUFAs (1.2 g/day) to placebo during a period of 12 weeks. This phase 
was followed by a further 40-week monitoring period. This study 
showed that fatty acids may prevent the progression in psychosis in 
young UHR patients. Recently, in a multicenter double-blind rand-
omized study, 304 participants meeting the ‘at-risk’ criteria were al-
located to treatment with either omega-3 plus cognitive-behavioral 
case management (CBCM) or placebo plus CBCM. The total length 
of treatment was six months. The data collected are still under evalu-
ation [16].
Another recent RCT was designed by Pawelczyk et al. [21] to 
compare the efficacy of 2.2 g/day of HUFAs or olive oil placebo added 
on to an antipsychotic medication with regard to symptom severity in 
patients suffering from first-episode schizophrenia. An improvement 
in psychopathology and the level of functioning was observed.
In the last few years, the first placebo-controlled trial on the 
association of omega-3 fatty acid and redox regulators for treat-
ing schizophrenia was conducted for 16 weeks by Bentsen and col-
leagues [22]. The participants were 99 patients with a diagnosis of 
schizophrenia or related psychoses who were divided in four groups 
(double placebo, active vitamins, active EPA or double active). The 
psychotic symptoms were assessed with PANSS. The results showed 
that adding E-EPA 2 g/day or vitamin E 364 mg•day/1 plus vitamin C 
1000 mg/day to antipsychotic drugs prevented the course of psycho-
sis, but only among patients with low levels of erythrocyte HUFAs. 
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On the contrary, combining EPA and the vitamins neutralized this 
detrimental effect. Emsley and colleagues [18] tested a combination of 
omega-3 polyunsaturated fatty acids (EPA 2 g/day and DHA 1 g/day) 
and a metabolic antioxidant, alpha-lipoic acid (α-LA 300 mg/day), 
as prevention treatment of relapse after antipsychotic discontinuation 
in subjects who were successfully treated for 2–3 years after a first-
episode of schizophrenia or schizoaffective disorder. Unfortunately, 
this study was affected by a small sample size and by premature ter-
mination of recruitment due to the high relapse rates and the severity 
of the relapse episodes. Finally, the results failed to support evidence 
that HUFAs + α-LA could be a worthwhile tool to maintenance antip-
sychotic treatment in relapse prevention.
Emsley et al. [29,30] also investigated the efficacy of long-chain 
fatty acids in reducing side effects due to conventional antipsychotic 
treatment in two randomized controlled trials. In particular, they ver-
ified the effects of omega-3 fatty acids supplementation on extrapy-
ramidal symptoms. The first study [29] found some beneficial effects 
of E-EPA (3 g/day) as add-on treatment in 40 patients with chronic 
schizophrenia, who had received a stable antipsychotic medication 
for at least six months on extrapyramidal symptoms assessed with 
the Extrapyramidal Symptoms Rating Scale. Moreover, the authors in 
this study also found a significant improvement of positive and nega-
tive symptoms measured with the PANSS. Unfortunately, the second 
study [30], disconfirmed these results in a larger sample of 77 patients 
with schizophrenia or schizoaffective disorders and tardive dyskine-
sia. In this trial, patients received E-EPA (2 g/day) or placebo for 12 
weeks. The E-EPA arm had an initial improvement in dyskinesia, but 
this result was not stable beyond six weeks. 
Four meta-analyses [25-28] of RCTs were conducted in order to 
establish if the available data support the use of omega-3 fatty acids in 
patients affected by schizophrenia or other psychotic disorders. The 
authors concluded that the evidence in favor of omega-3s as psycho-
tropic agents in schizophrenia is preliminary, and the findings remain 
yet inconclusive.
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Major Depressive Disorder
In 1998, Hibbeln [31] discovered a direct and powerful inverse 
association between fish consumption and the prevalence of major 
depression in a study aimed to test the hypothesis that a high con-
sumption of fish could be correlated with a lower annual prevalence 
of major depression. One year later, it was established that depression 
often co-occurs with cardiovascular disease, which is associated with 
elevated cholesterol and lower fatty acids plasma levels [32]. After this 
discovery, abnormal fatty acid compositions in the peripheral tissues 
(e.g., plasma, serum and red blood cells) of patients with depression 
have been reported extensively [33,34].
Twenty randomized controlled trials were conducted in order to 
evaluate the effectiveness of omega-3, EPA and DHA, in the treat-
ment of mild or moderate depressive disorder. Fatty acids were ad-
ministered both as a monotherapy and as supplementation to ongo-
ing pharmacotherapy or psychotherapy. Doses ranged from 0.4–4.4 
g/day of EPA and from 0.2–2.4 g/day of DHA. Ten RCTs investigated 
the efficacy of omega-3 fatty acids as an individual treatment strategy, 
but only seven of them reported that EPA and/or DHA had a positive 
effect on core depressive symptoms. Seven RCTs aimed to determine 
whether administering omega-3 fatty acids provides any additional 
benefit to conventional patient treatment (e.g., fluoxetine, citalopram 
or sertraline) for major depression. Five of these studies obtained a 
significant improvement of depressive symptoms [35-39]. However, 
the validity of these findings is limited by the heterogeneity of meth-
ods among different studies, including the use of unstandardized as-
sessment instruments of depressive symptoms, as well as considerable 
differences in doses and ratios of omega-3 fatty acids, the duration of 
the trials and the demographic and clinical characteristics of the sam-
ples. Further studies are needed to better understand the mechanisms 
of the antidepressant effects of HUFAs and to explain the reason for 
the discordant results published until now.
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Peet and Horrobin [35] conducted a 12-week study that showed 
improvement in patients treated with 1 g/day of ethyl-EPA (E-EPA) 
and who were refractory to selective serotonin uptake inhibitor mon-
otherapy for major depression. Findings showed that only 1 g/day 
of omega-3, but not 2 or 4 g/day, was effective in reducing depres-
sive symptoms measured with the Hamilton Depression Rating Scale 
(HDRS), the MADRS and the Back Depression Inventory (BDI) (ef-
fect size: 0.92) in adults with ongoing depression. Nemets et al. [40] 
designed a four-week placebo-controlled study on 20 subjects already 
undergoing antidepressant therapy and found better outcome results 
in the treatment group with E-EPA at the dosage of 2 g/day. The ef-
fect of omega-3 was significant from the second week of treatment, 
similarly to the time of response to antidepressants and resulting in an 
improvement of core depressive symptoms on the HDRS. The same 
authors [41] suggested that omega-3 may have a therapeutic benefit 
in 6–12-year-old children with major depression. Of the 20 patients 
who entered data analysis, 10 received placebo and 10 received ome-
ga-3 (0.4 g/day of EPA plus 0.2 g/day of DHA) for 16 weeks. Depres-
sion symptoms were assessed with the Childhood Depression Rating 
Scale, the Childhood Depression Inventory and the Clinical Global 
Impression (CGI). Su and colleagues [36] conducted an eight-week 
RCT comparing EPA (at the dose of 4.4 g/day) plus DHA (at the dose 
of 2.2 g/day) with placebo in augmentation to antidepressant in 22 
patients with major depression. They found encouraging results: par-
ticipants who were treated with omega-3 fatty acids had a significantly 
lower score of the HDRS. An interesting study on 36 pregnant wom-
en with major depressive disorder [42] compared omega-3 HUFAs 
monotherapy (2.2 g/day of EPA plus 1.2 g/day of DHA) with placebo. 
Twenty-four patients who finished the trial showed significantly low-
er depressive symptoms’ ratings on the HDRS, the Edinburgh Postna-
tal Depression Scale (EPDS), and the BDI. The findings of this study 
are remarkable because omega-3s are preferentially transported to the 
growing fetus during pregnancy, which can deplete fatty acid levels in 
mothers. 
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The beneficial effect of omega-3 fatty acids supplementation on 
depressive symptoms was also confirmed in elderly women (aged 66–
95 years) residents in a nursing home [43,44]. Within a context of an 
eight-week double-blind RCT, 46 women who received a diagnosis of 
depression were randomly assigned to the intervention group (1.67 g/
day of EPA plus 0.83 g/day of DHA) or the placebo group. Depressive 
symptoms, assessed with the Geriatric Depression Scale, quality of life 
assessed with the Short-Form 36-Item Health Survey and phospho-
lipids fatty acids’ profile improved. Nevertheless, the same authors in 
another study [45] measured some immunological parameters and 
cytokines in the same sample, but they did not find a significant ame-
lioration of the immunological function in the intervention group.
Currently, there is not a general consensus concerning the effi-
cacy of omega-3s in the treatment of depression. Rees and colleagues 
[46] found that omega-3 fatty acids were not superior over placebo 
in treating perinatal depressive symptoms. They administered 0.4 g/
day of EPA plus 1.6 g/day of DHA as a monotherapy to 26 pregnant 
women for six weeks. Similar results were collected by Freeman and 
colleagues [47], who did not detect significant differences between 
omega-3 HUFAs (EPA 1.1 g/day plus DHA at the dose of 0.8 g/day) 
and placebo on perinatal depressive symptoms measured with the 
HDRS and the EPDS. All 59 women enrolled in this trial received 
also a supportive psychotherapy for eight weeks.
In a similar way, omega-3s were not found superior to placebo in 
treating depressive symptoms in three other studies. Marangell et al. 
[48], Silvers et al. [49] and Grenyer et al. [50] obtained no significant 
improvement in the symptoms of depression in patients who were 
treated with similar doses of EPA and/or DHA (ranging 2–3 g/day) as 
sole therapy or in addition to antidepressive drug. These studies were 
different for sample size, duration and instruments to assess depres-
sive symptoms, but they drew the same conclusions.
Lespérance et al. (2011) [37] conducted an inclusive, double-
blind, randomized controlled trial on 432 patients with a major de-
pressive episode. They administered EPA (1.050 g/day) and DHA 
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(150 mg/day) for eight weeks to a sample with a heterogeneous ther-
apy (40.3% of the patients already received an antidepressant at the 
baseline). Omega-3 supplementation resulted in being superior over 
placebo only for the patients without comorbid anxiety disorders. 
Two studies investigated the effectiveness of omega-3s on depres-
sion and on cognitive functions. Rogers et al. [51] in a 12-week trial 
tested the efficacy of EPA plus DHA (0.6 g/day + 0.85 g/day) on mood 
and cognition in 218 patients with mild to moderate depression. More 
recently, Antypa and colleagues [52] treated 71 depressed patients 
with omega-3 fatty acids or placebo for four weeks. They evaluated 
cognitive reactivity with the Leiden Index of Depression Sensitivity-
Revised (LEIDS-R) and the Profile of Mood States (POMS), and de-
pressive symptoms were measured with the BDI. Both studies have 
not obtained favorable results on mood and cognition using omega-
3s.
Two trials compared the effectiveness of different doses of EPA 
or DHA in the treatment of depressive disorders. Mischoulon and 
colleagues in 2008 [53] enrolled 35 depressed outpatients that were 
randomized into one of three double-blind dosing arms for 12 weeks: 
1 g/day DHA; 2 g/day DHA; 4 g/day DHA. In this study, subjects 
who received 2 g/day or more DHA had a lower response rate (on the 
HDRS) compared to those who received 1 g/day. It is interesting to 
note that these findings are similar to Peet and Horrobin’s results [35]: 
E-EPA, as well as DHA appear more effective at lower doses. In the 
same year (2008), Jazayeri and colleagues [38] compared EPA at the 
low dosage of 1 g/day with fluoxetine (20 mg/day) in 60 patients with 
major depressive disorder for eight weeks. The results showed that a 
low dose of EPA may have similar therapeutic effects as fluoxetine.
A recent and larger eight-week RCT [54] compared the potential 
therapeutic effects of three differing doses, (i) EPA (1 g/day), (ii) DHA 
(1 g/day) or (iii) placebo (containing 980 mg of soybean oil per cap; 
four capsules/day), in 196 depressed patients. The authors reported a 
significant improvement in depressive symptoms in all three groups; 
neither EPA nor DHA were superior to placebo.
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Interesting results were obtained from one study that explored 
the association of omega-3 fatty acids and antidepressants in treat-
ing depressed patients [39]. The authors investigated the efficacy of 
combination therapy with citalopram plus omega-3 fatty acids (1.8 
g/day of EPA + 0.4 g/day of DHA + 0.2 g/day of other omega-3s) vs. 
citalopram plus placebo in 42 patients with initial depression. Com-
bined therapy showed grater improvements in depression symptoms 
assessed with HDRS, but did not enhance the speed of antidepressant 
response.
The effects of fish oil supplementation were also investigated in 
patients with major depression associated with coronary heart disease 
[55]. Carney and colleagues (2009) obtained negative results testing 
omega-3 in cardiopathic patients. They performed a 10-week RCT to 
evaluate the effects of ethyl-EPA (0.93 g/day) plus DHA (0.75 g/day) 
in addition to sertraline on symptoms of depression in 122 patients 
with major depressive disorder and coronary heart disease. The au-
thors did not find any superiority of treatment over placebo.
In conclusion, supplementation with HUFA in patients with ma-
jor depression seems useful in improving depressive symptoms, but 
the findings are not univocal. Systematic reviews and meta-analyses 
also provided controversial conclusions. Appleton and colleagues [56] 
reviewed 35 RCTs that included 329 adults and concluded that tri-
als investigating the effects of HUFAs on depression are increasing, 
but it is difficult to evaluate their results because of data heterogene-
ity. Bloch and Hannestad [57] outlined the methodological limits of 
available studies that affect the validity of results. On the contrary, 
other meta-analyses [58-60] indicated a more encouraging prospec-
tive in this field and concluded that omega-3 fatty acids produce a 
significant antidepressant effect. In particular, EPA seems to be more 
efficacious than DHA in treating depression. A more recent compre-
hensive meta-analysis [61] of RCTs confirmed that the use of omega-
3s as therapeutic agents was effective in patients with the diagnosis 
of major depression or depressive symptoms and suggested that pa-
tients with greater depressive severity and those meeting full criteria 
for a diagnosis of depressive disorder demonstrated greater treatment 
gains (Table 2).
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Study Dose and Method Sample Treatment Duration Results
Peet and Horrobin, 2002 
[35]
ethyl-EPA 1, 2 or 4 g/day add-on standard 
antidepressant treatment
70 patients resistant to 
antidepressant treatment
12 weeks ↓ depressive symptoms measured with HDRS, MADRS and BDI 
in the group treated with 1 g/day of HUFAs 
Nemets et al., 2002 [40] ethyl-EPA 2 g/day 20 patients 4 weeks ↓ depressive symptoms measured with HDRS from the second 
week of treatment
Nemets et al., 2006 [41] ethyl-EPA 0.4 g/day + DHA 0.2 g/day 20 patients 6–12 years-old 16 weeks ↓ depressive symptoms measured with CDRS, CDI and CGI
Su et al., 2003 [36] ethyl-EPA 4.4 g/day + DHA 2.2 g/day add-on 
existing antidepressant treatment
22 patients 8 weeks ↓ depressive symptoms measured with HDRS
Su et al., 2008 [42] ethyl-EPA 2.2 g/day + DHA 1.2 g/day 36 pregnant patients 8 weeks ↓ depressive symptoms measured with HDRS, EPDS and BDI
Rondanelli et al., 2010, 
2011 [43,44]
EPA 1.67 g/day + DHA 0.83 g/day add-on 
existing antidepressant treatment
46 elderly female residents 
in a nursing home
8 weeks ↓ depressive symptoms assessed with GDS, improvement of phos-
pholipids fatty acids’ profile 
Rees et al., 2008 [46] ethyl-EPA 0.4 g/day + DHA 1.6 g/day 26 pregnant patients 6 weeks no benefits on depressive symptoms
Freeman et al., 2008 [47] EPA 1.1 g/day + DHA 0.8 g/day 59 women 8 weeks no benefit on perinatal depressive symptoms
Lespérance et al., 2011 [37] EPA 1.050 g/day + DHA 150 mg/day 432 patients with a major 
depressive episode
8 weeks ↓ depressive symptoms only for the patients without comorbid 
anxiety disorders
Mischoulon et al., 2008 [53] DHA 1, 2, or 4 g/day 35 patients 12 weeks measured in the group in treatment with 1 g/day of HUFAs
Jazayeri et al., 2008 [38] EPA 1 g/day vs. fluoxetine 20 mg/day 60 patients 8 weeks ↓ depressive symptoms in both groups
Mischoulon et al., 2015 [54] EPA 1 g/day or DHA 1 g/day 196 patients 8 weeks EPA and DHA were not superior to placebo
Gertsik et al., 2012 [39] EPA 1.8 g/day + DHA 0.4 g/day + other 
omega-3 fatty acids 0.2 g/day + citalopram vs. 
placebo + citalopram
42 patients 9 weeks ↓ depressive symptoms measured with HDRS
Carney et al., 2009 [55] E-EPA (0.93 g/day) plus DHA (0.75 g/day) on 
depression in addition to sertraline
122 patients with major 
depression associated with 
coronary heart disease
10 weeks EPA and DHA were not superior to placebo
Table 2: Double-blind controlled trials of HUFAs in the treatment of depressive disorders. HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale.
EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA = ethyl-eicosapentaenoic acid; CDRS = Childhood Depression Rating Scale; CDI = Childhood Depression Inventory; EPDS = Edin-
burgh Postnatal Depression Scale; GDS = Geriatric Depression Scale; ↓ = decrease of; ↑ = increase of.
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Bipolar Disorders
In patients with a diagnosis of bipolar disorder, lower erythro-
cyte membrane levels of omega-3 fatty acids have been observed [62]. 
Based on this consideration, several investigators performed clinical 
trials to evaluate whether the implementation of these agents may im-
pact the clinical features of this disorder. To date, only seven RCTs 
on omega-3 treatment for bipolar disorders have been published. Ex-
cept for the first pioneering trial, they were all augmentation studies. 
Intervention length ranged from 6–16 weeks. Three of these [63-65] 
used EPA in addition to stable psychotropic medication. Two stud-
ies [66,67] explored the combination of EPA and DHA in addition to 
mood stabilizers or other usual treatments. In one trial [68], alpha-li-
nolenic acid was administered in association with stable psychotropic 
medications. Finally, in one add-on RCT [69], omega-3 was associat-
ed with cytidine or not as augmentation to a stable medication. Doses 
ranged from 0.3–6.2 g/day of EPA and from 0.2–3.4 g/day of DHA. 
The dose of alpha-linolenic acid was 6.6 g/day.
In the first trial, Stoll and colleagues [66] administered a com-
bination of EPA (6.2 g/day) and DHA (3.4 g/day) as a monotherapy 
to 14 patients, while 16 patients received placebo for 16 weeks. This 
study was affected by a large number (13 subjects) of drop-outs be-
cause of depression, mania, hypomania and mixed state. Outcomes 
revealed the efficacy of omega-3 in terms of the reduction and remis-
sion of depressive symptoms (HDRS), whereas no significant effects 
were registered on mania (Young Mania Rating Scale (YMRS)). These 
findings were replicated by Frangou and colleagues [63] in a 12-week 
controlled study including 75 patients treated with ethyl-EPA (1 or 
2 g/day) as adjunctive treatment to stable psychotropic medications. 
The same authors [64] reported increased brain levels of N-acetyl-as-
partate (NAA), a presumed marker of neuronal integrity, with 2 g/day 
of ethyl-EPA in 14 female patients with type I bipolar disorder that 
were treated with a stable dose of lithium. The study was controlled 
with placebo. The rise in NAA level provided the first evidence for a 
neurotrophic role of E-EPA treatment in bipolar disorder. 
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Concerning the manic phase, less encouraging findings were 
presented by Chiu et al. [67], who designed a four-week study to eval-
uate the efficacy of 4.4 g/day of EPA plus 2.4 g/day of DHA vs. placebo 
in addition to a fixed dose of valproate (20 mg/kg/day) in 15 patients 
with acute mania. The authors found a reduction in both groups of 
the YMRS scores from baseline, with no significant differences be-
tween omega-3 and placebo. Similar results were obtained in a larger 
RCT [65], which involved 121 patients with bipolar depression or 
rapid cycling bipolar disorder. The adjunction of 6 g/day of EPA to 
at least one mood stabilizer did not produce meaningful differences 
in reducing the severity of depressive or manic symptoms, assessed 
respectively with the Inventory for Depressive Symptomology total 
and the YMRS.
Gracious and colleagues [68] conducted a double-blind RCT of 
alpha-linoleic acid (ALA) as flax seed oil in children and adolescents 
with bipolar I or II disorder, assuming a stable psychotropic medica-
tion. In this study, there was a high rate of noncompliance with taking 
supplements because of the large number of capsules required (up to 
12 per day). Those who were treated with an adequate amount of ALA, 
demonstrated a significant improvement of overall symptom severity 
in comparison with the placebo group. Nevertheless, depression and 
mania measures did not show significant differences between treat-
ment and placebo groups. More recently, therapeutic properties of 
omega-3 fatty acids in bipolar disorder were further denied by Mur-
phy et al. [69] in a four-month RCT. Forty-five patients with a diag-
nosis of type I bipolar disorder, who were already treated with a mood 
stabilizer, were randomly assigned to three different groups consisting 
of omega-3 fatty acids plus cytidine, omega-3 fatty acid plus placebo 
or only placebo. In this study, supplementation with omega-3 did not 
produce a significant improvement in affective symptoms over an ex-
tended period of treatment. 
Overall, a moderate antidepressant effect was observed for ad-
junctive omega-3 agents compared to conventional therapy alone 
in the treatment of bipolar depression [66,67]. The small number of 
studies, the heterogeneity of HUFA doses and ratios and the small 
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sample sizes were important limitations to obtain reliable data on this 
topic. 
In summary, some beneficial effects of omega-3 HUFAs in bi-
polar disorders were observed. The conclusions of systematic reviews 
and meta-analyses [70-73] provided initial evidence that bipolar de-
pressive symptoms, but not manic symptoms, may be improved by 
adjunctive administration of omega-3 fatty acids (Table 3).
Table 3: Double-blind controlled trials of HUFAs in the treatment of bipolar disorders 
(depressive and maniac phases).
EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA = ethyl-eicosa-
pentaenoic acid; ALA = α-linoleic acid; ↓ = decrease of; ↑ = increase of.
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Anxiety Disorders
The hypothesis that omega-3s may have anxiolytic properties 
was formulated in the light of the frequent comorbidity between 
mood disorders and anxiety disorders and the effectiveness of some 
conventional pharmacotherapy on both disorders. Furthermore, low 
omega-3 erythrocyte membrane levels have been observed in patients 
with anxiety disorders [74,75,76]. Unfortunately, to our knowledge, 
there are no RCTs that have systematically investigated the effect of 
omega-3 PUFA in anxiety disorders. Only a small trial [77] showed 
a reduction in the levels of anxiety and tension in 24 substance abus-
ers. Participants received 2.2 g of EPA/day plus 0.5 g of DHA/day vs. 
placebo (vegetable oil) for three months. Anxiety continued to be sig-
nificantly decreased in the active treatment group after three months’ 
discontinuation. In each case, the evidence supporting the use of 
omega-3 PUFAs as an anxiolytic is currently insufficient [78].
Obsessive-Compulsive Disorder
Only one RCT about obsessive-compulsive disorder was pub-
lished by Fux and colleagues [79], who administered 2 g/day of EPA 
or placebo in augmentation of a stable dose of SSRIs to 11 patients 
(four of these received 40 mg; two received 30 mg; and two received 
60 mg of paroxetine daily; one patient was on 250 mg of fluvoxam-
ine daily; and two were on 40 mg of fluoxetine daily) for six weeks. 
The augmentation with HUFAs was not associated with significant 
improvement of anxious, obsessive-compulsive and depressive symp-
toms compared to placebo.
Attention Deficit Hyperactivity Disorder
Increasing attention has been given to the role of HUFAs in 
childhood developmental disorders. Since the 1980s, reduced HUFA 
levels have been reported in blood analysis of hyperactive children 
compared to healthy controls [80-83]. Recently, several double-blind 
placebo controlled trials have been conducted to assess the efficacy 
of omega-3 fatty acid in the treatment of children with ADHD [84-
95], but results are still discordant and disputable. Due to the con-
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siderable heterogeneity of published investigations, additional large-
cohort studies and well-designed clinical trials of ADHD patients are 
required. In particular, studies should be conducted with strict cri-
teria concerning methodological issues, such as an accurate DSM-5 
diagnosis of ADHD, a double-blind controlled design, the choice of 
reliable assessment instruments of symptoms and functioning, a clear 
definition of the doses and ratios of omega-3 fatty acids and of the 
possible association with conventional medications. 
If we examine the available data, seven [84,85,87-90] of thirteen 
RCTs investigating the efficacy of omega-3 fatty acids had a posi-
tive effect on ADHD-related symptoms. The remaining studies did 
not obtain significant improvement in ADHD symptoms [81,91-95]. 
Only two of these thirteen RCTs aimed to determine whether tak-
ing omega-3 fatty acids confers any additional benefit to conventional 
patient treatment (stimulant and non-stimulant medications): one 
found negative results [91] and one positive [90]. 
In particular, not very encouraging findings have been presented 
by six RCTs comparing the association of EPA and DHA to placebo. 
In a double-blind study performed by Stevens and colleagues [81], fif-
ty patients with ADHD-like symptoms received either placebo (olive 
oil) or HUFA supplementation (480 mg of DHA, 80 mg of EPA, 40 mg 
of arachidonic acid and 96 mg of gamma-linolenic acid/day) for four 
months. At baseline and at the end of the intervention period, both 
parents and teachers completed the Conners’ Abbreviated Symptom 
Questionnaires (ASQ) and the Disruptive Behavior Disorders (DBD) 
Rating Scale. Other additional neuropsychological tests were admin-
istered: the Conners’ Continuous Performance Test (CPT) and eight 
tests of cognitive ability of the Woodcock-Johnson Psycho-Educa-
tional Battery-Revised (WJ-R). No significant difference between ac-
tive group and placebo was observed for any rating scale comparing 
patients who completed the trial. HUFAs supplementation led to a 
significant behavioral improvement over placebo on only two of the 
16 outcome measures that were used (DBD-Conduct for Parents and 
the DBD-Attention for Teachers) and by intention-to-treat analysis 
only.
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In 2004, Hirayama and colleagues [92] also reported no evi-
dence of efficacy of omega-3 fatty acids compared to placebo in treat-
ing ADHD symptoms. In this double-blind placebo controlled trial, 
the majority of the 40 children did not receive ADHD medications 
(only six of them had been under conventional medications). They 
administered both DHA and EPA through fish oil-enriched food (the 
daily dose was approximately 100 mg of EPA and 500 mg of DHA) to 
twenty children with ADHD for two months. The control group (n = 
20) took indistinguishable food without fish oil. The authors meas-
ured ADHD related symptoms according to the DSM-IV criteria, ag-
gression, impatience and some cognitive features, but they did not 
find any significant changes in outcome measures. 
In another study (Johnson and colleagues) [93], seventy-five 
children and adolescents 8–18 years old with ADHD were included 
and treated with 558 mg EPA, 174 mg DHA and 60 mg gamma lin-
oleic acid daily, compared to placebo. Only one of the patients had 
been previously treated with a conventional drug for ADHD (methyl-
phenidate). Investigators found that only a subgroup of patients char-
acterized by the inattentive subtype of ADHD and associated neu-
rodevelopmental disorders showed a meaningful clinical response to 
omega-3 and omega-6 treatment. They concluded the study results 
were essentially negative and did not support the superiority of HU-
FAs over placebo.
Milte [94] performed a double-blind RCT, including 90 children 
7–12 years old with ADHD treated with EPA-rich oil (providing 1109 
mg of EPA and 108 mg of DHA), DHA-rich oil (providing 264 mg 
of EPA and 1032 mg of DHA) vs. an omega-6 HUFA oil during a 
period of four months. Children were taking no other medication. 
Despite that this study demonstrated no statistically-significant dif-
ferences between the two groups, the authors found that increased 
levels of erythrocyte DHA seemed associated with improved word 
reading and lower parent ratings of oppositional behavior. Interest-
ingly, a subgroup of 17 patients with learning difficulties exhibited 
superior benefits from the supplementation with omega-3 fatty acids.
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A more recent randomized, double-blind controlled trial (Wid-
enhorn-Müller et al.) [95] was conducted in 95 ADHD patients aged 
between six and 12 years who received omega-3 fatty acids or placebo 
for 16 weeks, not treated with medications for ADHD. The authors 
found less negative results than those from previous studies, but not 
yet satisfactory. Supplementation with EPA and DHA (600 mg of EPA 
and 120 mg of DHA daily) improved working memory function, but 
had no effect on other cognitive measures or behavioral symptoms in 
the study population.
Only one study concerning the use of DHA has been reported: 
using a randomized, double-blind design, Voigt and colleagues [91] 
tested the effect of 345 mg/day of DHA for four months upon 63 chil-
dren (6–12 years old) with ADHD, all receiving maintenance therapy 
with stimulant medication. Despite blood phospholipid DHA content 
being increased in the active treatment group, there was no statisti-
cally-significant improvement in any ADHD symptoms compared to 
placebo. 
On the other hand, some investigations have provided more 
promising findings. In particular, interesting results have been ob-
tained by the seven RCTs in which EPA and DHA were administered 
to ADHD patients and compared to placebo. 
Richardson and colleagues [84] published a pilot double-blind 
RCT investigating the efficacy of the combination of omega-3 and 
omega-6 fatty acids (daily dose of 186 mg of EPA, 480 mg of DHA, 
864 mg of linolenic acid and 42 mg of arachidonic acid) vs. placebo 
in 41 children with ADHD-related symptoms and specific learning 
disabilities. ADHD-type symptoms were assessed using the Conners’s 
Teacher Rating Scale. After 12 weeks of treatment, mean scores for 
cognitive problems and general behavior improved more in the group 
treated with HUFAs than placebo. More recently, these findings were 
replicated by the same authors [85]. They conducted a larger double-
blind placebo controlled RCT, including 117 children diagnosed with 
Developmental Coordination Disorder (DCD), which is character-
ized by deficit of motor functions and shows substantial overlap with 
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ADHD in terms of difficulties with organizational skills and attention. 
The active treatment provided a high ratio of omega-3 and omega-6 
fatty acids for three months. Despite no effects being reported on 
motor skills, HUFAs dietary supplementation led to improvement of 
reading, spelling and behavior in the treatment group compared to 
placebo. Subsequently, a one-way, uncontrolled crossover to active 
supplement followed for a further three months: similar changes were 
observed in the placebo-active group, while the original treatment 
group’s scores continued to improve. 
Sinn and Bryan (2008) on a large sample included 132 children 
aged 7–12 years with a diagnosis of ADHD [86]. Participants were 
enrolled in a 15-week double-blind controlled trial and were treated 
with 93 mg of EPA, 29 mg of DHA and 10 mg of gamma-linolenic 
acid daily, with or without a micronutrient supplement, and were 
compared to placebo. Children were not treated with ADHD medica-
tions. The results outlined that both groups treated with HUFAs im-
proved more than placebo subjects in some core ADHD symptoms, 
such as inattention, hyperactivity and impulsivity. These results were 
confirmed by the same authors (Sinn and Bryan) [87] in a 15-week 
crossover study. 
Bélanger et al. (2009), in a Canadian double-blind, one-way, 
crossover randomized trial [88], measured the impact on ADHD 
of omega-3 HUFAs, using equivalent quantities of omega-6 HUFAs 
(sunflower oil) as the control condition. Thirty seven subjects were 
enrolled, but only 26 children succeeded in completing the study. 
Participants did not receive any other medication. They were divided 
into two groups (A and B) and participated in a 16-week, double-
blind, one-way, crossover randomized study. In the first phase, Group 
A received the n-3 HUFA supplement, and Group B received placebo. 
During the second phase, Group B received the active n-3 HUFA sup-
plement that was continued in Group A. In the first phase of the study 
(Weeks 0–15), a meaningful improvement in inattention and global 
ADHD symptoms emerged in patients who received omega-3 treat-
ment (20 mg/kg/day–25 mg/kg/day of EPA and 8.5 mg/kg/day–10.5 
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mg/kg/day of DHA). These positive results were maintained during 
the second phase (the treatment crossover, Weeks 16–30) but did not 
reach in this phase statistical significance.
Kirby et al. [89] have assessed the effects of the administration of 
0.8 g/day fish oil (including 400 mg of DHA and 56 mg of EPA/day) 
on 450 healthy school-children. After a period of 16 weeks, the plasma 
ratio omega-6/omega-3 was measured, and patients were submitted 
to a series of cognitive tests to assess IQ, reading, language and writ-
ing skills, attention, working memory, impulsivity and hyperactivity. 
This RCT showed a significant improvement in impulsivity, evaluated 
with the Matching Familiar Figures Task (MFFT), handwriting and 
attentional capacity, evaluated with the Computerized Penmanship 
Evaluation Tool (COCOM) and a possible protective effect of omega-
3s on behavioral dysregulation, compared to placebo. 
In accordance with these findings, a six-month randomized 
double-blind controlled trial by Perera [90] indicated the efficacy of 
supplementation with a combined omega-3 and omega-6 preparation 
vs. placebo in 98 children with ADHD, refractory to methylphenidate 
treatment (all participants continued taking immediate-release meth-
ylphenidate during the study). In particular, omega-3 (600 mg/day) 
combined with omega-6 (360 mg/day) improved behavior and learn-
ing in restlessness, aggressiveness, completing work and academic 
performance, but not in inattention, impulsiveness and cooperation 
with parents and teachers.
A comprehensive meta-analysis conducted by Bloch et al. [96] of 
omega-3 fatty acids supplementation in children with ADHD found a 
small to modest effect size for EPA at high doses. Another recent me-
ta-analysis conducted by Sonuga-Barke et al. [97] concluded that free 
fatty acids (omega-3 supplements, omega-6 supplements and both 
omega-3 and omega-6 supplements) produce small, but significant 
reductions in ADHD symptoms. Besides, it provides evidence to jus-
tify the use of omega-3 fatty acids for ADHD as a supplement to other 
empirically-supported therapies. Gillies et al. [98] suggested that the 
efficacy of omega-3 fatty acids is supported only in combination with 
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omega-6 fatty acids. A recent review [99] found that randomized 
clinical trials with omega-3 HUFAs have reported small-to-modest 
effects in reducing symptoms of ADHD in children and that available 
findings need to be replicated in future investigations of nonpharma-
cological interventions in clinical practice (Table 4).
Autism Spectrum Disorders
The efficacy of HUFAs as a treatment consideration has also been 
taken into account in other developmental disorders, such as autism 
spectrum disorder [100,101]. There is some evidence to suggest that 
autism may involve a cellular functional deficiency or imbalance of 
omega-3 [100-102]. Studies focused on the deficit in the concentra-
tion of HUFAs complexed to membrane phospholipids in children 
with autism showed controversial results. Vancassel and colleagues 
[102] examined the concentration of fatty acids in plasma in a popu-
lation of children with autism and in another group of children with 
learning disabilities. This study reported a 23% reduction of DHA lev-
els in the group with autism compared to the control group, a reduc-
tion in the erythrocytes membrane concentration of omega-3 and a 
concomitant increase in the levels of saturated fatty acids [100,101]. 
In addition, some evidence showed that omega-3 may improve 
the course of chronic inflammatory diseases [103], frequently associ-
ated with autism and potentially related to its pathophysiology [104]. 
Considering that data collected from uncontrolled studies are af-
fected by severe limitations and that only three RCTs are available, ev-
idence is insufficient at the moment to determine whether HUFAs are 
effective for autism spectrum disorder. Actually, only one study [105] 
supported HUFAs supplementation to treat autism-related symp-
toms, while the remaining did not find any positive effects [106,107].
The first RCT is a double-blind, randomized, placebo-controlled, 
pilot study, performed by Amminger in 13 children (aged 5–17 years) 
with autistic disorder [105]. After six weeks, the group treated with 
EPA (840 mg/day) and DHA (700 mg/day) showed an improvement 
of hyperactivity and stereotyped behaviors. 
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Table 4: Double-blind controlled trials of HUFAs in the treatment of ADHD. 
Study Dose and Method Sample Treatment 
Duration 
Results
Voigt et al., 
2001 [91]
DHA 345 mg/day vs. placebo; with ADHD medication 63 children (6–12 years 
old) with ADHD
4 months no statistically-significant improvement in any ADHD symptoms compared to placebo
Richardson et 
al., 2002 [84] 
EPA 186 mg·g/day + DHA 480 mg/die + linolenic acid 
864 mg/die + arachidonic acid 42 mg/die vs. placebo 
41 children with AD-
HD-like symptoms
12 weeks mean scores for cognitive problems and general behavior improved more in the group trea-
ted with HUFAs than placebo 
Stevens et al., 
2003 [81] 
DHA 480 mg/day + EPA 80 mg/day + arachidonic 
acid 40 mg/day + gamma-linolenic acid 96 mg/day vs. 
placebo; no ADHD medications 
50 children with AD-
HD-like symptoms 
4 months no significant difference between active group and placebo was observed for any rating 
scale comparing patients who completed the trial
Hirayama et 
al., 2004 [92]
EPA 100 mg/die + DHA 500 mg/die vs. placebo; 
mostly without ADHD medications (only six subjects 
had been under medications)
40 children with ADHD 2 months no evidence of the efficacy of omega-3 fatty acids compared to placebo
Johnson et al., 
2009 [93] 
EPA 558 mg/die + DHA 174 mg/die + gamma linoleic 
acid 60 mg/die vs. placebo; only one patient with 
ADHD medication 
75 children and ado-
lescents 8–18 year old 
with ADHD
3 months no evidence of the efficacy of omega-3 fatty acids compared to placebo 
Bélanger et al., 
2009 [88] 
EPA 20–25 mg/kg/die + DHA 8.5–10.5 mg/kg/day vs. 
placebo; no ADHD medications
26 children 16-week improvement in inattention and global ADHD symptoms only in the first phase of the stu-
dy (Weeks 0–15)
Milte et al., 
2012 [94] 
EPA-rich oil (providing EPA 1109 mg and DHA 108 
mg), DHA-rich oil (providing EPA 264 mg and DHA 
1032 mg) vs. an omega-6 HUFAs oil; no ADHD me-
dications 
90 children (7–12 year 
old) with ADHD




EPA 600 mg/die + DHA 120 mg/die; no ADHD me-
dications
95 children (6–12 years) 
with ADHD
16 weeks improved working memory function, but no effect on other cognitive measures or behavio-




EPA 93 mg/day + DHA 29 mg/day + gamma-linolenic 
acid 10 mg/day vs. placebo; no ADHD medications
132 children (7–12 ye-
ars) with ADHD 
improved in inattention, hyperactivity and impulsivity in most ADHD scales in parents’ 
reports; no improvement in teacher reports; limits: no ADHD diagnosis (reported ADHD 
symptoms)
Perera et al., 
2012 [90] 
omega-3 + omega-6 vs. placebo; with ADHD medi-
cations
98 children (6–12 years) 
with ADHD diagnosis
6 months improved behavior and learning in restlessness, aggressiveness, completing work and aca-
demic performance, but not in inattention, impulsiveness and cooperation with parents and 
teachers
Kirby et al. 
[89]




16 weeks significant improvement in impulsivity, handwriting and attentional capacity and a possible 
protective effect of omega-3 on behavioral dysregulation, compared to placebo
EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid.
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The second double-blind, placebo-controlled trial was conduct-
ed by Voigt [106] and presented different conclusions. In particular, 
the authors did not show any improvement in core symptoms of 
autism after a dietary DHA supplementation of 200 mg/day for six 
months in a group of 48 children with autism. 
The third randomized, double-blind, placebo-controlled trial 
was conducted by Mankad et al. [107]. They designed a six-month 
trial of omega-3 fatty acid supplementation (1.5 g of EPA and DHA/
day) in comparison with placebo in 38 children (2–5 years old) with 
autism. This study did not support the hypothesis that high dose sup-
plementation of HUFAs in children with autism provides any efficacy 
in terms of improvement of core symptom domains or adaptive func-
tion.
Considering the scarcity of data in this field, we also reported 
the results from one case-report and one open-label study performed 
in patients with autism. The case report study [108] showed an im-
provement of symptoms in a child suffering from autism following 
treatment with EPA in the first time administered at a dose of 1 g/day, 
then at a dose of 3 g/day, for a period of four weeks. During the eight-
month follow-up phase, the improvements were maintained. The 
open-label study [109] carried out on 20 autistic children reported 
a significant improvement of the disease after three months of treat-
ment with omega-3, omega-6 and omega-9 at a dose of 1 g/day (1 g/
day). 
To date, one systematic review [110] about the efficacy of HUFAs 
in the treatment of autism spectrum disorders is available. The con-
clusions showed that the omega-6/omega-3 fatty acid ratio’s alteration 
during early life can affect major processes in brain development and 
induces aberrant behavior. Thus, changes in dietary omega-6/ome-
ga-3 supplies may contribute to reducing the incidence of symptoms 
related to autism. So far, the studies are still few and provided limited 
results; therefore, further investigations on a larger population are re-
quired to draw conclusions in this field.
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Aggression, Hostility and Impulsivity
In the last two decades, growing attention has been given to 
the potential role of omega-3 in clinical conditions characterized by 
high impulsivity, hostility and aggressive behaviors [5]. The discovery 
of low levels of EPA and DHA in the central nervous system of pa-
tients with impulsive-aggressive, self-harm and parasuicidal behav-
iors [111,112] has encouraged the investigators to perform trials on 
omega-3 implementation in this clinical population characterized by 
a high level of impulsivity and aggression with favorable results in 
terms of mood symptoms and control of impulsivity [113,114].
Two randomized, double-blind, placebo-controlled trials have 
been performed to analyze the effects of HUFA supplementation in 
populations without psychiatric diagnosis on aggression and impul-
sivity. Both showed positive results, but available data are limited by 
the heterogeneity of the study criteria. The first RCT [113] was con-
ducted by Hamazaki in a group of 41 healthy controls (21–30 years 
old) monitoring the episodes of aggressive behaviors and cognitive 
functions during three months. Participants daily received 1.5–1.8 g 
of DHA or placebo. Aggression toward others significantly increased 
in the control group, while it decreased in the DHA supplement 
group. No significant differences were observed on cognitive func-
tions. Another trial was conducted by Itomura et al. (2005) in 166 
healthy school children 9–12 years old in order to investigate whether 
fatty acid nutrition may affect physical aggression [114]. Eighty-three 
children received a fish oil-fortified diet, providing a daily intake of 
3.6 g of DHA and 0.84 of EPA for three months. Aggression against 
others and impulsivity were significantly decreased in the fish oil 
group, especially in girls. 
In a six-week RCT, Bradbury and colleagues (2004) [115] inves-
tigated the possible role of DHA in improving adaptation to perceived 
stress in a group of 47 healthy controls (18–60 years). They found a 
significant reduction in stress for both the fish oil (1.5 g/day of DHA) 
and the placebo groups, but the stress reduction for the fish oil group 
was significantly superior to that in the no-treatment controls. The 
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fish oil group obtained a more substantial stress reduction than the 
olive oil group, but the differences between treatments did not reach 
statistical significance.
Borderline Personality Disorder
The effects of omega-3 fatty acids supplementation has been 
studied in patients with personality disorders, who often show high 
levels of impulsive-behavioral dyscontrol and aggressiveness. Only 
two RCTs with a double-blind, randomized, placebo-controlled de-
sign have been conducted [116,117]. Both indicated the efficacy of 
HUFAs on borderline personality disorder (BPD) core symptoms, 
although they were different in diagnostic criteria, contemporary ad-
ministration of conventional medications and the doses and ratios of 
omega-3 fatty acids.
Zanarini and Frankenburg [116] performed the first RCT in a 
group of 30 female patients with a diagnosis of BPD who were treated 
for eight weeks with 1 g/day of E-EPA or placebo and without any 
other psychotropic medication. The results showed a significant effect 
of E-EPA on aggressive behaviors measured with the Modified Overt 
Aggression Scale (MOAS) and on depressive symptoms assessed with 
the Montgomery-Åsberg Depression Rating Scale (MADRS) com-
pared to placebo. In another study, published by Hallahan and col-
leagues [117], 49 patients with self-defeating behaviors (39 patients 
had received a diagnosis of BPD) were enrolled. Twenty-seven pa-
tients were randomly assigned to placebo, and 22 were treated with 
EPA at the dose of 1.2 g/day and DHA at the dose of 0.9 g/day for 
12 weeks. Omega-3s were added to the standard psychiatric thera-
pies. This RCT showed a significant improvement of affect (measured 
with the Beck Depression Inventory and the Hamilton for Depression 
Rating Scale (HDRS)), parasuicidal behaviors and stress reactivity in 
the treatment group. Aggressiveness, measured with the MOAS score, 
and impulsive behaviors, assessed with the Memory Delay Task, did 
not obtain a significant difference in the two groups. 
On the basis of this background, our research group performed 
a RCT in order to assess the efficacy and tolerability of omega-3 fatty 
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acids in combination with valproic acid in a group of 43 BPD pa-
tients [118] who were randomly assigned to two treatments for twelve 
weeks: (1) valproic acid (800–1300 mg/day) (plasma range: 50–100 
μg/mL); (2) EPA (1.2 g/day) and DHA (0.6 g/day) in combination 
with the same dose of valproic acid. Results indicated that the associa-
tion of omega-3 fatty acids and valproate was effective in reducing the 
severity of characteristic BPD symptoms, measured with the Border-
line Personality Disorder Severity Index (BPDSI), impulsive behavio-
ral dyscontrol, assessed with the Barratt Impulsiveness Scale (BIS-11), 
outbursts of anger, evaluated with the item “outburst of anger” of the 
BPDSI, and self-mutilating conduct, measured with the Self-Harm 
Inventory (SHI) (Table 5).
Table 5: Double-blind controlled trials of HUFAs in the treatment of impulsivity and 
borderline personality disorder. 
EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA = ethyl-eicosa-
pentaenoic acid; BPDSI = Borderline Personality Disorder Severity Index; ↓ = decrease 
of; ↑ = increase of.
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Substance Dependence
According to research, proinflammatory cytokines are responsi-
ble for the physical and psychological symptoms concomitant to crav-
ing, and EPA can neutralize these molecules’ toxic effects in the brain 
[75,119]. The neuroprotective effect of omega-3s on the production of 
serotonin and its action on the prefrontal cortex may also help with 
maintaining executive ability, both compromised during withdrawal 
and craving. Only two studies have been conducted to assess the ef-
ficacy of omega-3 fatty acid in the treatment of substance dependence 
[75,120]. The first study [75] evaluated the efficacy of EPA + DHA 
(3 g/day) for a period of three months on anxiety symptoms in ad-
dicted patients. The group treated with omega-3s showed a significant 
reduction in anxiety when compared to placebo. These results were 
replicated and confirmed by the following study performed by the 
same authors [120].
Anorexia Nervosa
Two studies, focused on the deficit in the concentration of HU-
FAs complexed to membrane phospholipids in patients with anorexia 
nervosa, showed similar results. Holman and colleagues [121] exam-
ined the concentration of fatty acids in plasma in a population of eight 
hospitalized anorexia nervosa fasting females compared to 19 healthy 
female adults <25 years old. Subjects with anorexia nervosa had defi-
ciencies of essential fatty acids and showed decreased concentrations 
of total omega-6 and omega-3 acids, compared to the control group; 
this indicates compensatory changes in non-essential fatty acids and 
can lead to a consequent problem in terms of membrane structure 
and fluidity. Furthermore, Langan and Farrell [122] reported a con-
comitant significantly reduction of omega-3 and omega-6 in plasma 
phospholipids’ concentration in a group of 17 patients (16 females, 
one male) hospitalized for anorexia nervosa compared to 11 normal 
females. 
Only two trials have been conducted to assess the efficacy of 
omega-3 fatty acid in the treatment of anorexia nervosa. In the first 
pilot open label study, conducted by Ayton [123], seven patients be-
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tween 13 and 22 years old with anorexia nervosa, restrictive subtype, 
received 1 g/day EPA in addition to standard treatment for three 
months. This small study showed a general improvement in sleep, 
mood, dry skin and constipation (measured with Weight 4 Height 
software, the Eating Disorder Inventory (EDI-2), the Morgan-Russell 
Average Outcome Scale (MRAOS), BDI-2, the Children’s Global As-
sessment Scale (CGA-S) and CGI-S. 
Negative results in this clinical population were reported by Bar-
barich and collaborators [124]. Twenty six subjects with anorexia ner-
vosa (10 subjects were restricting-type; six subjects were restricting 
and purging only-type; and 10 subjects were binge eating/purging-
type) participated in a six-month trial of fluoxetine (20–60 mg/die). 
Using a randomized, double-blind design, subjects were assigned to 
either nutritional supplements (600 mg of DHA and 180 mg of arachi-
donic acid daily, tryptophan, vitamins, minerals) or placebo. Patients 
were evaluated with: the Frost Multidimensional Perfectionism Scale 
(FMPS), the State-Trait Anxiety Inventory (STAI-Y) and Yale-Brown 
Obsessive Compulsive Scale (Y-BOCS). They were also weighed at 
weekly intervals for the first eight weeks, at two-week intervals for 
the following six weeks and at 4-week intervals for a further 12 weeks. 
There were no significant differences in weight gain per week be-
tween subjects treated with fluoxetine plus nutritional supplements 
vs. fluoxetine plus placebo. Moreover, there were no significant dif-
ferences between groups in mean changes of anxiety or obsessive and 
compulsive symptoms. 
Adverse Effects
Omega-3 fatty acids did not induce serious adverse effects and 
were generally well tolerated: most common side effects reported in 
clinical trials were nausea and a fishy aftertaste, but they were mild 
and rarely induced discontinuation [125]. The Panel of The European 
Food Safety Authority (EFSA) concluded that the available data are 
insufficient to establish a tolerable daily intake (UL) of DHA, EPA and 
DPA individually or in combination, but the supplementation with 
EPA and DHA up to 5 g/day is not dangerous for the general popula-
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tion [126]. In particular, EPA and DHA are generally recognized as 
safe and well tolerated at dose up to 5 g/day in terms of bleeding risk, 
as pointed out by Yokoyama et al. [127] and Tanaka et al. [128]. In ad-
dition, doses up to 5 g/day, consumed for a maximum period of 12–16 
weeks, do not significantly affect glucose regulation in both healthy 
and diabetic subjects [119--131] and do not increase infection risk 
by the activation of inappropriate inflammatory responses [132]. The 
intake of EPA and DHA at the same dose and up to 16 weeks does not 
induce alteration of lipid peroxidation and does not increase cardio-
vascular risk [133]. Combined intake of EPA and DHA at the dose of 
2–6 g/day and intake of DHA at the dose of 2–4 g/die are responsible 
for an LDL concentration increase (3%), but do not affect cardiovas-
cular risk. At last, an intake of EPA at the maximum dose of 4 g/day 
does not induce significant changes in LDL plasma levels [134].
Conclusions
In the last decade, the role of long-chain HUFAs in the treatment 
of several psychiatric diseases has gradually increased, as confirmed 
by the growing number of randomized controlled trials testing the 
efficacy of essential fatty acid, especially omega-3 HUFA, supplemen-
tation. Nevertheless, an overall consensus about their efficacy is still 
lacking, and the findings of most of trials are controversial and incon-
clusive. Differences in methods, including sample size, selection crite-
ria, choice and dosage of fatty acids (i.e., EPA, or DHA, or a combina-
tion of the two, or the addition of omega-6 HUFAs) and the duration 
of supplementation often make results not comparable.
The main evidence for the efficacy of EPA and DHA has been 
obtained in mood disorders. In particular, omega-3 fatty acids seem 
to be useful in preventing and improving depressive symptoms at a 
low dose of 1 g/day; EPA seems to be more efficacious than DHA; 
patients with more severe depression showed greater treatment gains. 
However, due to the considerable heterogeneity of the investigations, 
additional large cohort studies and well-designed clinical trials are 
warranted. Concerning bipolar disorder, the results of systematic 
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reviews and meta-analyses suggested a potential beneficial role of 
omega-3 fatty acids in addition to stable medications in treating de-
pressive symptom at the approximate dose of 1–2 g/day, but did not 
support their use in attenuating mania. Furthermore, studies using 
a combination of EPA and DHA reported a statistically-significant 
improvement in symptoms of bipolar depression, whereas trials us-
ing a single compound did not. In schizophrenia, little evidence of a 
meaningful clinical effect was reported, and current data do not al-
low us either to refuse or support the use of omega-3 fatty acids in 
psychotic patients. However, adverse effects of antipsychotics, in par-
ticular metabolic abnormalities and extrapyramidal symptoms, may 
benefit from the addition of EPA or a combination of EPA and DHA. 
In ADHD disorder, several RCTs have been performed, but the main 
findings have reported small-to-modest effects of omega-3 HUFAs 
in reducing ADHD symptoms in children. Most promising results 
in this field have been reached by studies using EPA at high doses 
or the association of omega-3 and omega-6 fatty acids. Anyway, the 
relative efficacy of these agents was modest compared to the currently 
available pharmacotherapies. To date, a small number of clinical trials 
have explored the impact of HUFAs on impulsive and aggressive be-
haviors and a growing number of studies has been conducted in order 
to test the efficacy of these agents in borderline personality disorder. 
Results are encouraging, although this area of psychopathology needs 
to be explored in depth by future investigations. In autism spectrum 
disorders, only two RCTs with opposite results are available, whereas 
there is a substantial lack of data about the use of omega-3 fatty acids 
in anxiety disorders and obsessive-compulsive disorder. The majority 
of trials assessing patients with mood disorders did not investigate 
changes in anxiety symptoms, although anxiety is frequently associ-
ated with depression or mania. HUFAs were not found efficacious in 
treating eating disorders and substance use disorders. Concerning 
tolerability, RCTs considered in this review share a common finding: 
omega-3 fatty acids did not induce serious adverse effects. A survey of 
studies concluded that omega-3 are generally recognized as safe and 
well tolerated at doses up to 5 g/day for a maximum period of 12–16 
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weeks. Several authors have assessed the effects of omega-3 HUFA 
administration in terms of bleeding risk, glucose metabolism, lipid 
profile, infection risk and cardiovascular function with a general con-
sensus about their harmlessness.
In summary, preliminary findings on omega-3 fatty acids in psy-
chiatric populations allow us to consider these naturally-derived and 
well-tolerated psychotropic agents as a promising therapeutic tool. 
However, their efficacy in treating specific mental disorders or clus-
ters of psychiatric symptoms is not sufficiently proven, as the findings 
from studies and reviews are too divergent to draw any conclusion.
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